Rising PSA fol treatment for malignant neoplasm of prostate

This code signifies a biochemical recurrence of prostate cancer, specifically indicated by an increase in prostate-specific antigen (PSA) levels after a patient has undergone definitive treatment for a malignant prostate neoplasm. It represents a post-treatment elevation of PSA, suggesting persistent or recurrent disease, without current evidence of metastatic spread.

Use this code when documentation indicates a rising PSA level in a patient with a history of prostate cancer who has completed primary treatment (e.g., prostatectomy, radiation therapy). The medical record should clearly state "rising PSA," "biochemical recurrence," or similar language, along with the patient's history of treated prostate malignancy.

• Always sequence a personal history of malignant neoplasm of prostate (Z85.46) as a secondary diagnosis when using this code.
• Do not use this code for initial diagnosis of prostate cancer or for PSA elevation prior to definitive treatment.
• Distinguish from codes for active prostate malignancy (C61) or metastatic disease, as this code implies biochemical recurrence without current evidence of structural disease.